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T
he International Association of Dia-
betes and Pregnancy Study Groups
(IADPSG) was formed in 1998 as an
umbrella organization to facilitate collabo-
ration between the various regional and na-
tional groups that have a primary or
signiﬁcant focus on diabetes and preg-
nancy. The principal objectives of IADPSG
are to foster an international approach to
enhancingthequalityofcare,facilitatingre-
search,andadvancingeducationintheﬁeld
of diabetes in pregnancy.
During 11–12 June 2008, the IADPSG
sponsored an International Workshop-
ConferenceonGestationalDiabetesDiag-
nosis and Classiﬁcation in Pasadena, Cal-
ifornia. More than 225 conferees from 40
countries reviewed published results of
the Hyperglycemia and Adverse Preg-
nancy Outcome (HAPO) study, addi-
tionalunpublishedHAPOstudyﬁndings,
and results of other work that examined
associations of maternal glycemia with
perinatal and long-term outcomes in off-
spring. Conferees then held regional cau-
cuses to consider clinical implications of
the information that had been presented.
On13June2008,theIADPSGConsensus
Panel (with representation from the 10
memberorganizationsoftheIADPSGand
other organizations with an interest in di-
abetes and pregnancy) was convened.
MembersoftheIADPSGConsensusPanel
are listed in the online-only appendix,
available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1848/DC1.
Subsequently, the IADPSG Consensus
PanelreviewedfurtherHAPOstudyresults.
Through this process, the consensus sum-
marized in this report was reached.
Thisreportrepresentstheopinionsof
individual members of the IADPSG Con-
sensus Panel and does not necessarily re-
ﬂectthepositionoftheorganizationsthey
represent. It is expected that this report
will be considered by diabetes, obstetric,
and other organizations and will serve as
the basis for internationally endorsed cri-
teriaforthediagnosisandclassiﬁcationof
diabetes in pregnancy.
Gestational diabetes mellitus (GDM),
a common medical complication of preg-
nancy,isdeﬁnedas“anydegreeofglucose
intolerance with onset or ﬁrst recognition
during pregnancy” (1,2). The initial crite-
riaforitsdiagnosiswereestablishedmore
than 40 years ago (3) and, with modiﬁca-
tions (4), remain in use today. These cri-
teria were chosen to identify women at
high risk for development of diabetes af-
ter pregnancy (5) or were derived from
criteria used for nonpregnant individuals
(6) and not necessarily to identify preg-
nancies with increased risk for adverse
perinatal outcome. There is consensus
that overt diabetes during pregnancy,
whethersymptomaticornot,isassociated
with signiﬁcant risk of adverse perinatal
outcome. Therisk of adverse perinatal out-
come associated with degrees of hypergly-
cemia less severe than overt diabetes is
controversial. Several factors contribute to
this longstanding controversy.
Some have attributed risks of adverse
outcomes associated with GDM, such as
birth weight that is large for gestational
age (LGA), excess fetal adiposity, and
higher rate of cesarean section, to con-
founding characteristics, such as obesity,
more advanced maternal age, or other
medical complications, rather than glu-
cose intolerance (7–9). Bias of caregivers
toward expectation of adverse outcomes
may increase morbidity due to increased
intervention (10). Some suggest that cri-
teria currently in wide use for the diagno-
sis of GDM are too restrictive and that
lesser degrees of hyperglycemia increase
risk of adverse perinatal outcomes (11–
16). Conversely, others believe that sys-
tematic efforts to identify GDM should be
stopped unless data become available to
link signiﬁcant morbidities to speciﬁc de-
grees of glucose intolerance (8). Lack of
international uniformity in the approach
to ascertainment and diagnosis of GDM
has been a major hurdle (2).
Questions have been raised regarding
cost-effectiveness and beneﬁt of detecting
and treating GDM. Recent recommenda-
tions of the U.S. Preventive Services Task
Force, the U.K. National Health Service,
and the Canadian Task Force on the Peri-
odic Health Examination assert that there
is not sufﬁcient high-level evidence to
make a recommendation for, or against,
screening for GDM (17–19). Recently, a
cost-effectiveness study undertaken by
the U.K. National Institute for Health and
Clinical Excellence concluded that
“screening, diagnosis, and treatment of
gestationaldiabetesiscost-effective”(20).
As currently deﬁned (1,2), GDM in-
cludes a subgroup with more severe hy-
perglycemia (similar to that seen in
preexisting diabetes) that presents special
issues concerning management during
pregnancy and postpartum follow-up.
The issues raised by inclusion of this sub-
groupwiththosewithGDMareofgreater
concern because of the rising prevalence
ofobesity,type2diabetes,andothermet-
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groups (21–23).
The HAPO study was designed to clar-
ifyrisksofadverseoutcomeassociatedwith
degrees of maternal glucose intolerance less
severethanthosewithovertdiabetesduring
pregnancy (24). HAPO study results
(25,26) were considered in depth in arriv-
ingattherecommendationsfordiagnosisof
GDM presented in this report. Recommen-
dations for detection of overt diabetes dur-
ing pregnancy are based on the opinions of
the IADPSG Consensus Panel members be-
cause information from prospective studies
or appropriately designed clinical trials is
not available.
THE HAPO STUDY— Theobjective
of the HAPO study was to clarify associa-
tions of levels of maternal glucose lower
than those diagnostic of diabetes with peri-
natal outcome (24,25). This was accom-
plished by performing a 75-g oral glucose
tolerance test (OGTT) on a heterogeneous,
multinational, multicultural, ethnically di-
verse cohort of 25,000 women in the
third trimester of gestation. Medical care-
givers were blinded to status of glucose tol-
erance except when predeﬁned criteria
were met (fasting plasma glucose [FPG]
5.8 mmol/l [105 mg/dl] and/or 2-h
plasmaglucose11.1mmol/l[200mg/dl])
(24).Itwasanticipatedthatthiswouldpro-
vide data on associations between maternal
glycemia and risk of speciﬁc adverse out-
comes that could be used to derive interna-
tionallyacceptablecriteriafordiagnosisand
classiﬁcation of GDM.
Primary outcomes in the blinded
HAPO cohort were birth weight 90th
percentile, primary cesarean section de-
livery, clinically deﬁned neonatal hypo-
glycemia, and cord C-peptide 90th
percentile.Secondaryoutcomeswerepre-
clampsia,pretermdelivery,shoulderdysto-
cia/birth injury, hyperbilirubinemia, and
intensive neonatal care.
Importantly, there were continuous
graded relationships between higher ma-
ternalglucoseandincreasingfrequencyof
the primary outcomes, independent of
other risk factors (25). Similar associa-
tions were also observed for secondary
outcomes (25,26). Associations did not
differ among centers; thus, the results are
applicable to all centers and can be used
globally to develop outcome-based crite-
ria for classifying glucose metabolism in
pregnancy. Because associations were
continuous with no obvious thresholds at
which risks increased, it was concluded
that a consensus was required to translate
these results into clinical practice.
OTHER STUDIES
REVIEWED— Data from numerous
studies are consistent with HAPO study re-
sults. In Pima Indians, Pettitt et al. (27)
found that maternal plasma glucose con-
centrationduringpregnancy(measured2h
after a 75-g load) had a continuous associ-
ation with adverse pregnancy outcomes
(LGAandcesareansection).ADanishstudy
ofpregnantwomenwithmildglucoseintol-
erance but without GDM found a linear as-
sociationbetweenmaternal2-hglucoseand
cesareandelivery,spontaneouspretermde-
livery, shoulder dystocia, and macrosomia
after adjustment for confounders (28). An-
other analysis of that cohort (11) showed a
linearrelationshipbetweenmaternalfasting
glucose and macrosomia. The Toronto Tri-
Hospital Study showed continuous associ-
ations between maternal glycemia and
adverse pregnancy outcomes (29). Sacks et
al. (30) found associations between FPG
andthe2-hvalueona75-gOGTTandmac-
rosomiainamixedethnicU.S.cohort(61%
Hispanic).InamultiethnicU.S.population,
Ferrara et al. (16) found risk of severe mac-
rosomia, neonatal hypoglycemia, and hy-
perbilirubinemia increased with increasing
numberofabnormalglucosevaluesaccord-
ing to current American Diabetes Associa-
tion cut points (2,5) among women who
didnotmeetNationalDiabetesDataGroup
criteria for GDM (31).
There are studies relating maternal gly-
cemia to long-term outcomes in offspring.
Pima Indian data demonstrated a direct as-
sociation between maternal glycemia (in
womenwhoseglucoseconcentrationswere
in the range found in the blinded HAPO
cohort) and offspring’s long-term relative
weightanddegreeofglucosetolerance,and
it was a risk factor for diabetes and/or im-
paired glucose tolerance during the female
offspring’s pregnancies (32). Hillier et al.
(33)assessedoffspringofmothersreceiving
care in a large, diverse health care practice.
Adiposity in offspring at 5–7 years of age
was signiﬁcantly associated with measures
of maternal glycemia (50-g glucose chal-
lenge and/or 100-g OGTT) during preg-
nancy. This suggests that we may expect
similar outcomes in offspring from the
HAPO study.
TRANSLATION OF HAPO
STUDY RESULTS FOR
DIAGNOSIS OF GDM— Some
studies cited above and others were pre-
sented at the IADPSG Pasadena meeting.
The results were consistent with HAPO
ﬁndings indicating that associations be-
tween maternal glycemia and adverse out-
comes are continuous across the range of
glucose concentrations below levels diag-
nostic of diabetes (25,26). As a result of the
extensive efforts used to standardize proce-
dures for participant enrollment (24,25),
laboratory analyses (34), data collection
(24,25), and analysis of results (25,26),
HAPO data were used as the basis for the
new GDM diagnostic thresholds recom-
mended in this report.
HAPO data show strong linear asso-
ciations of risks for 90th percentiles of
birthweight,cordC-peptide,andpercent
body fat with each of three measures of
maternal glucose (FPG, 1-h, and 2-h
post–75-g load). In determining the rec-
ommendations for diagnostic thresholds,
associations with these outcomes were
used to select glucose concentrations as
potential diagnostic threshold values
(supplemental Fig. 1). Published data
support this decision. Fetal macrosomia
(LGA) is a major indicator of the effects
of hyperglycemia during pregnancy
(12,35,36). Associations of LGA and ex-
cessadipositywithfetalhyperinsulinemia
are strong and independent of confound-
ers (26,37,38). This is supported by ex-
periments in pregnant monkeys (39).
Risks of difﬁcult delivery and maternal/
neonatal damage associated with fetal
macrosomia (9,40) were conﬁrmed in
large populations (41,42). Long-term
risks associated with fetal macrosomia in
infants of women with GDM (indepen-
dent of confounders) include childhood
overweight (43,44) and metabolic factors
that may increase risk of cardiovascular
disease (CVD) (45).
In the HAPO study, frequencies of
study outcomes were compared across
the entire distribution of glucose concen-
trations, with the lowest glucose concen-
tration ranges used as the reference for
calculation of odds ratios (ORs) (25).
However, the IADPSG Consensus Panel
decided that for selection of diagnostic
thresholds,meanvaluesforFPG,1-h,and
2-hOGTTplasmaglucoseconcentrations
(4.5, 7.4, and 6.2 mmol/l, respectively)
fortheentirestudycohortshouldbeused
as reference. Concentrations at which
ORs for speciﬁc outcomes in adjusted
models reached predeﬁned values, with
glucosemodeledasacontinuousvariable,
were then determined. After review of
these data, the IADPSG Consensus Panel
concluded that the predeﬁned value for
the OR at the threshold relative to the
IADPSG Consensus Panel
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were also considered, see OTHER CONSIDER-
ATIONSbelow).Finally,proportionsofpar-
ticipants who would be identiﬁed by
measurement of FPG only, FPG plus 1-h
glucoseconcentration,andFPGplusboth
1-h and 2-h plasma glucose concentra-
tions were considered.
Diagnostic recommendations
The stepwise consideration of the HAPO
study data described above led to the rec-
ommendation of the values for FPG, 1-h,
and 2-h plasma glucose concentration (Si
and conventional) indicated in Table 1 as
diagnostic thresholds. These thresholds
are the average glucose values at which
odds for birth weight 90th percentile,
cord C-peptide 90th percentile, and
percent body fat 90th percentile
reached 1.75 times the estimated odds of
these outcomes at mean glucose values,
based on fully adjusted logistic regression
models. At least one of these thresholds
must be equaled or exceeded to make a
diagnosis of GDM. Measuring FPG alone
identiﬁed 8.3% of the cohort as having
GDM. Adding measurement of the 1-h
plasma glucose identiﬁed an additional
5.7%; adding the 2-h plasma glucose
measurement identiﬁed another 2.1% of
the cohort. Among the HAPO cohort,
11.1% had only one elevated result, 3.9%
had two elevated results, and 1.1% had
elevation of all three results. In addition,
1.7% of the cohort was unblinded due to
an FPG or 2-h plasma glucose value on
the enrollment OGTT above predeﬁned
values of 5.8 mmol/l (105 mg/dl) or 11.1
mmol/l (200 mg/dl), respectively (25).
Thus, by these new criteria, the total inci-
dence of GDM was 17.8%; the FPG plus
1-h plasma glucose levels identiﬁed a
large majority of these individuals.
Adjusted ORs and 95% CIs for asso-
ciations between maternal glucose and
HAPOstudyoutcomesareinsupplemen-
tal Table A. ORs are for the difference in
glucose between the mean glucose value
and the recommended threshold. In ad-
dition to the outcomes used to deter-
mine the thresholds, there were strong
associations between maternal glucose
and preeclampsia (ORs 1.40–1.57) and
shoulder dystocia and/or birth injury
(1.30–1.43).
The frequencies of HAPO study out-
comes when all three glucose measures
were below threshold values and when
any one or more values were greater than
or equal to threshold concentration were
compared (supplemental Table B). The
frequency of birth weight, C-peptide, or
percent infant body fat 90th percentile
was approximately twofold greater when
any of the glucose values were greater
than or equal to the threshold. The fre-
quency of preeclampsia was twofold
higher when one or more glucose values
met or exceeded threshold, and frequen-
cies of preterm delivery and primary ce-
sarean section were 45% higher.
Other considerations
Measurement of glucose. The frequen-
cies and ORs for outcomes on which the
recommended diagnostic thresholds are
based increase substantially over rela-
tivelysmallchangesinglucoseconcentra-
tion (supplemental Fig. 1 and Table A).
Therefore, to achieve reliable diagnosis
and classiﬁcation of hyperglycemia in
pregnancy, clinical laboratories must
measure venous plasma or serum glucose
using an enzymatic method with high ac-
curacy and precision. This includes proper
sample collection and processing to mini-
mizepre-analyticglycolysisandproperlab-
oratory analysis (34,46). Capillary and
venous plasma glucose concentrations dif-
ferandarenotinterchangeable,andconver-
sion factors do not accurately estimate
equivalent values (46).
Alternative OR/threshold combina-
tions. Consideration was given to glu-
cose values and outcome frequencies for
adjusted ORs of 1.5 and 2.0. The thresh-
oldORof1.5identiﬁed25%ofthecohort
with one or more glucose values that met
or exceeded the threshold. The propor-
tion of the cohort with FPG equal to or
greaterthanthresholdatORsof1.5,1.75,
or2.0(5.0,5.1,and5.3mmol/lor90,92,
or 95 mg/dl, respectively) differed sub-
stantially, representing 12, 8, and 4%,
respectively.AtORsof2.0,frequenciesof
birth weight, cord serum C-peptide, or
percent infant body fat 90th percentile
inthosemeetingthresholdweremodestly
higher than those for OR 1.75 (supple-
mental Table B), but the number of par-
ticipants meeting threshold decreased
from 16.1 to 8.8%, meaning that the
higher thresholds would fail to identify
many cases with nearly comparable risk
of adverse outcomes.
Rounding threshold values to easy-to-
remember numbers. Values such as 5.0
and 9.0 mmol/l (90 and 155 mg/dl, re-
spectively) for FPG and 2-h plasma glu-
cose would be somewhat easier to
remember than those indicated in Table
1. However, this strategy is not feasible.
First, as indicated above, arbitrarily
choosing an FPG threshold of 5.0 mmol/l
(90 mg/dl) would substantially affect the
proportion of women meeting a diagnos-
tic threshold. Second, both Si and stan-
dard units are widely used, and the
numbers are not equally easy or difﬁcult
to remember for both units of measure.
The values in Table 1 represent the best
choice from a clinical perspective, and
they meet the predeﬁned strength of as-
Table 1—Threshold values for diagnosis of GDM or overt diabetes in pregnancy
To diagnose GDM and cumulative proportion of HAPO cohort equaling or exceeding those
thresholds
Glucose measure
Glucose concentration
threshold* Above threshold (%)
mmol/l mg/dl Cumulative
FPG 5.1 92 8.3
1-h plasma glucose 10.0 180 14.0
2-h plasma glucose 8.5 153 16.1†
To diagnose overt diabetes in pregnancy
Measure of glycemia Consensus threshold
FPG‡ 7.0 mmol/l (126 mg/dl)
A1C‡ 6.5% (DCCT/UKPDS standardized)
Random plasma glucose 11.1 mmol/l (200 mg/dl)  conﬁrmation§
*One or more of these values from a 75-g OGTT must be equaled or exceeded for the diagnosis of GDM. †In
addition,1.7%ofparticipantsintheinitialcohortwereunblindedbecauseofFPG5.8mmol/l(105mg/dl)
or 2-h OGTT values 11.1 mmol/l (200 mg/dl), bringing the total to 17.8%. ‡One of these must be met to
identifythepatientashavingovertdiabetesinpregnancy.§Ifarandomplasmaglucoseistheinitialmeasure,
the tentative diagnosis of overt diabetes in pregnancy should be conﬁrmed by FPG or A1C using a DCCT/
UKPDS-standardized assay.
Diagnosis of hyperglycemia in pregnancy
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Randomized treatment trials and
choice of threshold values. Two ran-
domized controlled trials comparing ac-
tive treatment versus standard obstetric
care for mild GDM have been conducted
during the years in which the HAPO
study was carried out (47,48). In both
randomized controlled trials, treatment,
achieved primarily by diet/lifestyle modi-
ﬁcation, resulted in reduced birth weight
and frequency of LGA births and pre-
eclampsia. Recruitment processes and
glycemic values of participants were not
identical in the randomized controlled
trials and the HAPO observational study.
However, there was substantial overlap
betweenglucosevaluesusedforinclusion
in the randomized controlled trials and
those recommended in this report as new
threshold values. Furthermore, frequen-
cies of outcomes such as LGA or birth
weight 90th percentile and preeclamp-
sia in usual care versus treatment arms of
the randomized controlled trials are sim-
ilar to those observed in the HAPO study
among women with one or more glucose
values that meet or exceed the threshold,
compared with those with all values be-
lowthreshold(supplementalTableB).Al-
though not directly comparable, it was
concludedthatresultsofthetworandom-
ized controlled trials (47,48) and HAPO
(25,26) are highly complementary.
DETECTION AND
DIAGNOSIS OF OVERT
DIABETES DURING
PREGNANCY— The International
Workshop-Conferences on GDM have
deﬁned the condition as “any degree of
glucoseintolerancewithonsetorﬁrstrec-
ognition during pregnancy” (1,2). The
deﬁnition has applied whether or not in-
sulin is used for treatment or hyperglyce-
mia persists after pregnancy. The
possibility that unrecognized glucose in-
tolerance antedated the pregnancy is not
excluded. This facilitates a uniform strat-
egy for detection and classiﬁcation of
GDM but has limitations. As ongoing ep-
idemics of obesity and diabetes result in
more type 2 diabetes in young women,
the number who are undiagnosed (before
pregnancy) is increasing (49,50). The
needtoidentifythesewomenandaddress
perinatal risks that may be particular to
their greater degree of hyperglycemia is
becoming more important. The IADPSG
Consensus Panel reviewed the current
knowledge base during the June 2008
IADPSG meeting. The recommendations
summarizedbelowaretheopinionsofthe
IADPSG Consensus Panel.
The issue of classiﬁcation of women
with likely prepregnancy diabetes (overt
diabetes) ﬁrst noted during pregnancy
was addressed via presentations by experi-
enced clinicians/researchers (Yasue Omori,
Lois Jovanovic, Elisabeth Mathiesen, and
Siri Kjos), accompanied by interactive dis-
cussion. Several arguments were made for
identifying as a distinct group women with
overt diabetes:
● Increased risk of congenital anomalies
in offspring (51).
● Risk of diabetes complications (ne-
phropathy and retinopathy) requiring
treatment during pregnancy (52).
● Need for rapid treatment and close fol-
low-up during pregnancy to ensure
prompt restoration of normal glycemia
(53,54).
● Need to ensure conﬁrmation and ap-
propriate treatment of diabetes after
pregnancy.
Identiﬁcation of overt diabetes
When and how to identify women with
overtdiabetesduringpregnancy(notpre-
viously diagnosed) and how to deﬁne
overtdiabeteswereconsideredduringthe
IADPSG Pasadena meeting and subse-
quently. There was uniform agreement
that this assessment should be made dur-
ingtheinitialvisitforprenatalcare.There
was debate about performing universal
early testing or limiting testing to those
womenclassiﬁedashighriskaccordingto
locally deﬁned criteria. It was acknowl-
edged that background population prev-
alence of diabetes in young women and
extent of previous testing for metabolic
disturbances vary greatly in different re-
gions.Furthermore,ithasnotbeendeter-
mined whether universal testing early in
pregnancy to detect overt diabetes is ei-
ther of clinical value or cost-effective.
IADPSG Consensus Panel members
favored use of any available certiﬁed lab-
oratorymeasureofglucose(FPG,random
plasma glucose, or A1C) for initial detec-
tion of possible cases. An expert commit-
tee recently recommended that an A1C
value 6.5% (measured in a laboratory
standardized/aligned with the Diabetes
Control and Complications Trial
[DCCT]/UK Prospective Diabetes Study
[UKPDS] assay) be used for diagnosis of
diabetes outside pregnancy (55). Al-
though many IADPSG Consensus Panel
membersfavoredusingA1Cfordetection
of overt diabetes in pregnancy, it was not
feasible to recommend a single test to use
exclusively. Cost and standardization of
A1C testing are issues for consideration,
and hemoglobin variants are prevalent in
somepopulations.Attendingtheﬁrstpre-
natalvisitinthefastingstateisimpractical
in many settings. Consensus thresholds
recommendedfortheindividualglycemia
measures are indicated in Table 1. A ten-
tativediagnosisofovertdiabetesbasedon
measurement of random plasma glucose
must be conﬁrmed with either an FPG or
A1C value greater than or equal to the
threshold using a DCCT/UKPDS stan-
dardized/aligned method (56).
Other considerations
Timing of the initial test. It is desirable
to detect overt diabetes in pregnancy as
early as possible to provide an opportu-
nity to optimize pregnancy outcome.
However, there is variability in time of
enrollment for prenatal care beyond the
control of health care providers. Accord-
ingly, no limit is placed on the timing of
initial assessment for detection of overt
diabetesinpregnancy.However,ifenroll-
ment is at 24 weeks’ gestation or later and
overt diabetes is not found, the initial test
should be followed by a 75-g OGTT.
Indeterminate results of initial testing.
It was recognized that any assessment of
glycemia in early pregnancy would also
result in detection of milder degrees of
hyperglycemiashortofovertdiabetes.Re-
cently, it was reported that higher ﬁrst-
trimester FPG levels (lower than those
diagnosticofdiabetes)areassociatedwith
increased risks of later diagnosis of GDM
and adverse pregnancy outcomes (57).
However, there have not been sufﬁcient
studies performed to know whether there
is beneﬁt of generalized testing to diag-
nose and treat GDM before the usual
window of 24–28 weeks’ gestation.
Therefore, the IADPSG Consensus Panel
does not recommend routinely perform-
ing OGTTs before 24–28 weeks’ gesta-
tion.ItisrecommendedthatanFPGvalue
in early pregnancy 5.1 mmol/l (92
mg/dl) also be classiﬁed as GDM.
SUMMARY OF DETECTION
STRATEGY— The overall strategy
recommended by the IADPSG Consensus
Panel for detection and diagnosis of hy-
perglycemic disorders in pregnancy is
summarized in Table 2. Two discrete
phases are included. The ﬁrst is detection
of women with overt diabetes not previ-
IADPSG Consensus Panel
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pregnancy.Universalearlytestinginpop-
ulations with a high prevalence of type 2
diabetes is recommended, especially if
metabolic testing in this age-group is not
commonly performed outside of preg-
nancy. Well-designed studies should be
conductedtodeterminewhetheritisben-
eﬁcial and cost-effective to perform an
OGTT in women who do not have overt
diabetes at early testing but have indeter-
minate nondiagnostic results. The second
phase is a 75-g OGTT at 24–28 weeks’
gestation in all women not previously
found to have overt diabetes or GDM.
CONCLUSIONS
Immediate implications
These recommendations have wide-
spread implications. The strategy out-
lined in Table 2 will ﬁnally lead to using a
75-gglucosedoseforanOGTTinallclin-
icalsettingsinoroutsideofpregnancy.In
someregionsand/orcountries,thisrepre-
sents a substantial change in long-
established practices. Glucose testing
earlyinpregnancytodetectovertdiabetes
and again with a 75-g OGTT at 24–28
weeks’ of gestation in all pregnancies not
already diagnosed with overt diabetes or
GDM by early testing represents funda-
mental changes in strategies for detection
and diagnosis of hyperglycemia in preg-
nancy. In most areas, using the outcome-
linked diagnostic criteria in Table 1 and
the detection strategy in Table 2 will sub-
stantiallyincreasethefrequencyofhyper-
glycemic disorders in pregnancy.
However, this is consistent with the high
prevalence of obesity and disorders of
glucose metabolism in the general popu-
lation of young adults (21,22) and with
recent reports of a rising prevalence of
GDM and preexisting overt diabetes in
pregnant women (49).
Future considerations
In future clinical practice, simpler and
more cost-effective strategies that do not
require performing an OGTT on most
pregnant women may be developed. In
the HAPO study, risks of some adverse
outcomes were low when FPG was 4.4
mmol/l (80 mg/dl). However, it was
thought that using FPG to potentially
identify pregnancies at very low risk for
GDM and for adverse outcomes requires
furtherevaluation.Similarly,furthereval-
uation of A1C results from the HAPO
study, results from other populations, or
new integrated tests of glycemia with a
shorter timeframe than A1C might serve
this purpose.
The HAPO study was a basic epide-
miological investigation that for the ﬁrst
time conclusively identiﬁed strong con-
tinuous associations of maternal glucose
levels below those diagnostic of diabetes
with several perinatal outcomes. It was
not a clinical trial, but two randomized
controlled trials of treatment of mild
GDM have been carried out successfully
in participants with glucose values that
overlap with the thresholds recom-
mended in this report. However, it is
likely that additional well-designed ran-
domized controlled trials and other clini-
cal studies will be needed to determine 1)
cost-effective therapeutic strategies for
treatment of GDM diagnosed by the
IADPSGConsensusPanel–recommended
criteria; 2) optimal glycemic treatment
targets;3)appropriatefollow-upofmoth-
ers to determine risks for later develop-
ment of diabetes, other metabolic
disorders, or CVD risk factors; and 4) fol-
low-up of children to assess potential as-
sociations of maternal glycemia with
long-termrisksofobesity,alteredglucose
metabolism, and CVD risk factors.
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